ATE553112T1 - Ttk in der diagnose und als therapeutisches target bei krebs - Google Patents

Ttk in der diagnose und als therapeutisches target bei krebs

Info

Publication number
ATE553112T1
ATE553112T1 AT02709637T AT02709637T ATE553112T1 AT E553112 T1 ATE553112 T1 AT E553112T1 AT 02709637 T AT02709637 T AT 02709637T AT 02709637 T AT02709637 T AT 02709637T AT E553112 T1 ATE553112 T1 AT E553112T1
Authority
AT
Austria
Prior art keywords
ttk
methods
genes
cancer
diagnosis
Prior art date
Application number
AT02709637T
Other languages
English (en)
Inventor
Christoph Reinhard
Anne Jefferson
Vivien Chan
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE553112T1 publication Critical patent/ATE553112T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
AT02709637T 2001-02-21 2002-02-21 Ttk in der diagnose und als therapeutisches target bei krebs ATE553112T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27125401P 2001-02-21 2001-02-21
PCT/US2002/005278 WO2002068444A1 (en) 2001-02-21 2002-02-21 Ttk in diagnosis and as a therapeutic target in cancer

Publications (1)

Publication Number Publication Date
ATE553112T1 true ATE553112T1 (de) 2012-04-15

Family

ID=23034823

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02709637T ATE553112T1 (de) 2001-02-21 2002-02-21 Ttk in der diagnose und als therapeutisches target bei krebs

Country Status (9)

Country Link
EP (1) EP1377596B1 (de)
JP (2) JP4429604B2 (de)
KR (1) KR100876327B1 (de)
CN (2) CN100578227C (de)
AT (1) ATE553112T1 (de)
AU (1) AU2002244112B2 (de)
CA (1) CA2438092C (de)
NZ (1) NZ527421A (de)
WO (1) WO2002068444A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1480995A4 (de) * 2002-02-12 2006-09-13 Chiron Corp Cks1-INHIBITOREN
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
EP1572118A4 (de) * 2002-12-20 2010-07-14 Millennium Pharm Inc Verfahren und zusammensetzungen zur behandlung von krebs mit 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216
JP4721903B2 (ja) * 2004-01-29 2011-07-13 大日本住友製薬株式会社 新規腫瘍抗原蛋白質及びその利用
CN102747141A (zh) * 2004-12-08 2012-10-24 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
PL2325306T3 (pl) * 2005-02-25 2014-07-31 Oncotherapy Science Inc Szczepionki peptydowe do zastosowania w nowotworach płuc, wykazujących ekspresję polipeptydów TTK, URLC10 lub KOC1
JP4647456B2 (ja) * 2005-10-11 2011-03-09 オンコセラピー・サイエンス株式会社 新規基質を用いたｔｔｋ活性抑制剤のスクリーニング方法
CA2635718A1 (en) * 2005-12-27 2007-08-09 Genentech, Inc. Methods of using hedgehog kinase antagonists to inhibit hedgehog signaling and to treat hedgehog mediated disorders
WO2008072777A2 (en) * 2006-12-13 2008-06-19 Oncotherapy Science, Inc. Ttk as tumor marker and therapeutic target for lung cancer
US8492356B2 (en) 2007-12-21 2013-07-23 University Health Network Methods of inhibiting tumor growth using TTK antagonists
WO2010007756A1 (ja) * 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
HUE032643T2 (en) * 2011-01-21 2017-10-30 Basilea Pharmaceutica Ag Use of BUBR1 as a biomarker for response to furazanobenzimidazoles
IL264173B2 (en) 2016-07-18 2025-05-01 Univ Health Network Solid forms of ttk inhibitor
CN117065023B (zh) * 2023-06-16 2025-11-21 华中科技大学同济医学院附属协和医院 Ttk基因及ttk抑制剂在治疗血管损伤后再狭窄中的功能及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056756A2 (en) * 1999-03-23 2000-09-28 Mount Sinai School Of Medicine Of New York University Prolactin regulatory element binding protein and uses thereof
WO2001030964A2 (en) * 1999-10-22 2001-05-03 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets

Also Published As

Publication number Publication date
JP2004526716A (ja) 2004-09-02
KR100876327B1 (ko) 2008-12-31
CN1492875A (zh) 2004-04-28
CA2438092A1 (en) 2002-09-06
KR20030076695A (ko) 2003-09-26
WO2002068444A1 (en) 2002-09-06
CN101732717A (zh) 2010-06-16
JP4838835B2 (ja) 2011-12-14
CN100578227C (zh) 2010-01-06
EP1377596A4 (de) 2005-07-13
NZ527421A (en) 2005-05-27
JP4429604B2 (ja) 2010-03-10
EP1377596B1 (de) 2012-04-11
EP1377596A1 (de) 2004-01-07
AU2002244112B2 (en) 2007-05-10
JP2009143890A (ja) 2009-07-02
CA2438092C (en) 2011-08-09

Similar Documents

Publication Publication Date Title
Pirsaheb et al. Current advances of carbon dots based biosensors for tumor marker detection, cancer cells analysis and bioimaging
Verdoes et al. A nonpeptidic cathepsin S activity-based probe for noninvasive optical imaging of tumor-associated macrophages
EP1377596A4 (de) Ttk in der diagnose und als therapeutisches target bei krebs
Schmidt et al. The development of a liquid biopsy for head and neck cancers
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
WO2023004087A3 (en) Compositions and methods for cancer detection
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
MX2018011725A (es) Metodo para emplear expresion genica para determinar pronostico de cancer de prostata.
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
DE602006015966D1 (de) Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie
Maiques et al. A preclinical pipeline to evaluate migrastatics as therapeutic agents in metastatic melanoma
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
Hajmohammadi et al. Biomarkers and common oral cancers: Clinical trial studies
WO2023004079A3 (en) Compositions and methods for detection of liver cancer
WO2017217807A3 (ko) Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물
BRPI0412110A (pt) genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos
RU2469651C2 (ru) Способ прогнозирования эффективности неоадъювантной химиотерапии больных раком молочной железы
EA202192289A1 (ru) Способы мечения эукариотных клеток многоклеточного организма, а также лечения и/или диагностики рака с использованием модифицированных моносахаридных соединений
WO2003083102A3 (en) Cancer associated protein phosphatases and their uses
CY1115258T1 (el) Μεθοδοι και χρησεις που περιλαμβανουν τις γενετικες παρεκκλισεις του ναv3 και την παρεκκλινουσα εκφραση πολλαπλων γονιδιων
Que et al. New strategy for antimetastatic treatment of lung cancer: a hypothesis based on circulating tumour cells
Ma et al. Pan-cancer analysis of ADAMs: A promising biomarker for prognosis and response to chemotherapy and immunotherapy
WO2009019366A3 (fr) Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal
BRPI0608429A2 (pt) método e kit para prognóstico ou avaliação da eficácia do tratamento de um tumor sólido em um paciente de interesse; e método para a identificação de marcadores que sejam prognósticos de um tumor sólido